

PRESS RELEASE

Granted U.S. Patent

Hørsholm, Denmark – September 15, 2026

AFYX Therapeutics Granted U.S. Patent for Intranasal Ketamine Treatment of Cluster Headache

AFYX Therapeutics A/S today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,136, entitled *"Intranasal Administration of Ketamine to Cluster Headache Patients."*

The patent, which is owned by AFYX, covers methods involving the intranasal administration of ketamine for the treatment of cluster headache. The granted patent includes claims relating to both chronic and episodic cluster headache and specifically encompasses S-ketamine hydrochloride, also known as esketamine, administered intranasally.

The patent strengthens AFYX's intellectual-property position in the United States for its proprietary intranasal esketamine programme, which is being developed to address the significant unmet medical need among patients suffering from cluster headache. The program is expected to enter phase 2B clinical testing in 2027. In a previous phase 2A study the intranasal ketamine administration was shown to reduce pain in 60% of the patients within approximately 20-30 minutes.

Cluster headache is a severely debilitating neurological condition characterised by recurrent attacks of intense pain, typically around one eye or one side of the head. Despite available acute and preventive treatments, many patients continue to experience insufficient relief, treatment limitations or substantial effects on their daily lives.

"The issuance of this U.S. patent represents an important milestone for AFYX and further strengthens the foundation for our esketamine programme," said Dr. Claus Møller-San Pedro, CEO and co-founder of AFYX Therapeutics. "Cluster headache is an exceptionally painful and disabling condition for which there remains a clear need for additional treatment options. This patent supports our ambition to develop a convenient intranasal treatment that may ultimately make a meaningful difference for patients."

The patent grant complements AFYX's existing international intellectual-property portfolio and represents another important step in the continued development and future commercialisation of the company's intranasal esketamine programme.



About AFYX Therapeutics

AFYX Therapeutics is a Danish biopharmaceutical company focused on reversed innovation—the reformulation and repurposing of established pharmaceutical substances and technologies to address significant unmet medical needs.

AFYX develops and commercialises products within head and neck cancer, obstetrics, cluster headache, pain and addiction, working both directly and through international partners.

For further information, please contact:

Dr. Claus J. Møller-San Pedro **CEO and co-founder**

AFYX Therapeutics A/S

Email: cm@afyxtx.com

Website: www.afyxtx.com

